<DOC>
	<DOCNO>NCT01706835</DOCNO>
	<brief_summary>This phase 1 open-label study investigate pharmacokinetics aldoxorubicin administer 30 minute infustion every 3 week 8 cycle subject advance solid tumor .</brief_summary>
	<brief_title>Study Investigate Pharmacolkinetics Aldoxorubicin ( INNO-206 ; DOXO-EMCH ) Administered 30 Minute Infusion Every 3 Weeks Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description>An Open-Label Phase 1 Study Investigate Pharmacokinetics Aldoxorubicin Administered 30 Minute Infusion Every 3 Weeks Subjects Advanced Solid Tumors .</detailed_description>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>1 . Age â‰¥18 year , male female . 2 . Histologically cytologically confirm malignant solid tumor relapse refractory standard therapy . 3 . Subjects receive prior radiation therapy stable central nervous system ( CNS ) metastasis progression brain metastasis CT/MRI scan last 4 week . 4 . Capable provide informed consent comply trial procedure . 5 . Eastern Cooperative Oncology Group performance status ( ECOG PS ) 02 . 6 . Life expectancy &gt; 12 week . 7 . Measurable evaluable disease . 8 . Women must able become pregnant ( e.g . postmenopausal least 1 year , surgically sterile , practice adequate birth control method ) duration study . [ Adequate contraception include : oral contraception , implanted contraception , intrauterine device implant least 3 month , barrier method conjunction spermicide. ] . 9 . Women child bear potential must negative serum urine pregnancy test Screening Visit nonlactating . 10 . Geographic accessibility site . 1 . Palliative surgery , chemotherapy , immunotherapy and/or radiation treatment le 4 week prior Screening Visit . 2 . Exposure investigational agent within 30 day Screening Visit . 3 . Laboratory value : Screening serum creatinine great equal 1.5 mg/dL , alanine aminotransferase ( ALT ) great 3 time upper limit normal ( ULN ) 5 time ULN liver metastasis , total bilirubin great 3 time ULN , white blood cell ( WBC ) count &lt; 3500/mm3 , absolute neutrophil ( ANC ) count &lt; 2000/mm3 , platelet concentration &lt; 100,000/mm3 , hematocrit level &lt; 25 % female &lt; 28 % male ( transfusion allow screen ) . 4 . Clinically evident congestive heart failure ( CHF ) &gt; class II New York Heart Association ( NYHA ) guideline . 5 . Serious , clinically significant cardiac arrhythmia , define existence absolute arrhythmia ventricular arrhythmia classify Lown III , IV V. 6 . Recent history ( within 6 month ) current sign active coronary artery disease without angina pectoris . 7 . Serious myocardial dysfunction define scintigraphically ( MUGA , myocardial scintigram ) ultrasound determine absolute leave ventricular ejection fraction ( LVEF ) &lt; 45 % predict . 8 . Known history HIV infection . 9 . Active , clinically significant serious infection require treatment antibiotic , antiviral antifungal . 10 . Major surgery within 4 week prior treatment . 11 . Substance abuse condition might interfere subject 's participation study evaluation study result . 12 . Any condition unstable could jeopardize subject 's participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>aldoxorubicin</keyword>
	<keyword>phase 1</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>INNO-206</keyword>
</DOC>